{"id":4787,"date":"2024-07-09T11:51:41","date_gmt":"2024-07-09T11:51:41","guid":{"rendered":"https:\/\/digitaltradecenter.com\/index.php\/2024\/07\/09\/new-pill-can-increase-chances-of-ivf-success-study-finds\/"},"modified":"2024-07-09T11:51:41","modified_gmt":"2024-07-09T11:51:41","slug":"new-pill-can-increase-chances-of-ivf-success-study-finds","status":"publish","type":"post","link":"https:\/\/digitaltradecenter.com\/index.php\/2024\/07\/09\/new-pill-can-increase-chances-of-ivf-success-study-finds\/","title":{"rendered":"New pill can increase chances of IVF success, study finds"},"content":{"rendered":"
\n

A pill for couples struggling to conceive with IVF treatment has been found to increase the chances of pregnancy, scientists say.<\/p>\n

Researchers said initial trials of the drug – known as OXO-001 and created by Spanish biotech company Oxolife – showed “promising” results.<\/p>\n

<\/div>\n

It acts directly on the inner lining of the womb to improve the embryo implantation process during fertility treatment.<\/p>\n

Around 96 infertile women who were aged 40 or under and were receiving fertility treatment – either IVF or intracytoplasmic sperm injection (ICSI) with donor eggs – at 28 centres across Europe took part in the new study, between September 2021 and January 2023.<\/p>\n

They were either given a placebo or OXO-001 – taken twice daily, one menstrual cycle before the embryo transfer and five weeks after.<\/p>\n

<\/div>\n

Researchers found “ongoing pregnancy rates” measured 10 weeks after embryo transfer were 46.3% for patients treated with OXO-001 – compared with 35.7% for those given a placebo.<\/p>\n

This is a “clinically significant finding”, they said, presenting their study to the European Society of Human Reproduction and Embryology’s (ESHRE) 40th annual meeting in Amsterdam.<\/p>\n

They said there was also a clinically meaningful increase in the number of women who went on to have a live birth.<\/p>\n

The live birth rate was 42.6% for women who took the new pill compared with 35.7% among those who took the placebo, according to the study – also being published in the journal Human Reproduction.<\/p>\n

Women in both groups suffered similar side-effects including headaches, nausea, vomiting, gastrointestinal issues and dizziness – most of which were mild to moderate.<\/p>\n

The drug had already gone through safety checks in early studies – known as pre-clinical trials.<\/p>\n

It is now to be tested on a larger group of women, including those who are using their own eggs.<\/p>\n

Oxolife chief executive Dr Agnes Arbat said: “Most rounds of IVF or ICSI still end in failure – many because a viable embryo does not implant.<\/p>\n

“A simple-to-take pill that materially improves the chance of success would therefore be of huge benefit to those who want a baby. This proof-of-concept phase two study shows that hope is now a step closer.”<\/p>\n

She added: “This study was purposefully designed to include only women who used donor eggs so it could single out the true effect of OXO-001 on the endometrium.<\/p>\n

“However, we believe OXO-001 has the potential to work equally well in those using their own eggs, and we are already planning a pivotal phase three clinical trial in this more extensive group to support product registration.”<\/p>\n<\/p>\n

This post appeared first on sky.com<\/div>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

A pill for couples struggling to conceive with IVF treatment has been found to increase the chances of pregnancy, scientists say. Researchers said initial trials of the drug – known as OXO-001 and created by Spanish biotech company Oxolife – showed “promising” results. It acts directly on the inner lining of the womb to improve <\/p>\n","protected":false},"author":1,"featured_media":4788,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":{"0":"post-4787","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-science"},"_links":{"self":[{"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/posts\/4787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/comments?post=4787"}],"version-history":[{"count":0,"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/posts\/4787\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/media\/4788"}],"wp:attachment":[{"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/media?parent=4787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/categories?post=4787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/digitaltradecenter.com\/index.php\/wp-json\/wp\/v2\/tags?post=4787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}